

Helsinn & MGI Pharma Announce Completion Of Pivotal Phase 3 Trials Of Palonosetron | Evaluate

Monday, June 29, 2015

[Subscriber Login](#)

 Evaluate™

[How We Use Cookies](#)

[Products & Solutions](#)

[News & Insight](#)

[About Us](#)

[Support](#)

[Contact Us](#)

Welcome: Guest | [Login](#) or [Register](#)

Helsinn & MGI Pharma Announce Completion Of Pivotal Phase 3 Trials Of Palonosetron

Source Press Release

Company [Helsinn Group](#), [MGI Pharma](#)

Tags Phase III, Gastro-Intestinal

Date January 16, 2002

Lugano, Switzerland and Minneapolis, MN -- January 16, 2002 -- Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and [MGI Pharma](#), Inc., (Nasdaq: MOGN) an oncology-focused pharmaceutical company based in Minneapolis, today announced that patient treatment is completed and the data analysis is underway for the pivotal Phase 3 trials of their [investigational](#) agent, [Palonosetron](#). [Palonosetron](#) is a potent, highly selective [5-HT3](#)-receptor antagonist in development in North America and Europe for the prevention of chemotherapy-induced nausea and vomiting (CINV). Submission of the New Drug Application (NDA) for [Palonosetron](#) is now planned to occur in the third quarter of 2002.

The Phase 3 clinical trial program was initiated in April 2000 and was designed to compare intravenous (IV) [Palonosetron](#) to currently marketed [5-HT3](#) antagonists. The trials were conducted at more than 130 medical centers across North America and Europe, with more than 1,800 cancer patients receiving either highly- or moderately-emetogenic chemotherapy. Based on the extended half-life of [Palonosetron](#) and the results of a Phase 2 trial, the efficacy of [Palonosetron](#) in the Phase 3 trial is being assessed over Day 2 through Day 5 following treatment, in addition to the primary efficacy measure of complete response during the 24-hour period after the start of chemotherapy.

"We are pleased to have completed all patient treatment and to have begun analysis of the data collected in the [Palonosetron](#) Phase 3 clinical program," said Luigi Baroni, senior director of Scientific Affairs Division at HELSINN. "The Phase 2 clinical trial results were promising, and we are hopeful that the Phase 3 [Palonosetron](#) data will demonstrate that it can make a difference for cancer patients suffering from CINV."

"The half-life of other available [5-HT3](#) receptor antagonists ranges from approximately five to nine hours, whereas [Palonosetron](#) has a plasma elimination half-life of nearly 40 hours," notes Dr. John MacDonald, senior vice president of Research and Development at MGI. "The activity seen with [Palonosetron](#) in the Phase 2 trial, coupled with its safety profile observed to date, led to the initiation of a Phase 3 program to assess the ability of the drug to provide prolonged protection against CINV with a single dose."

Source: Evaluate™ ©2015 Evaluate Ltd, All rights reserved.

[Print](#)

[Bookmark](#)

[HOME](#)

[OUR PRODUCTS](#)

[LATEST NEWS & INSIGHT](#)

[SUPPORT](#)

[CONTACT US](#)

[SHARE THIS PAGE](#)

[Privacy](#)

[Terms & Conditions](#)

[Legal](#)

[Careers](#)

[Sitemap](#)

[WorkSpace Terms & Conditions](#)

Join Us On



[Twitter](#)

[HOW WE USE COOKIES](#)

Dr. Reddy's Laboratories, Ltd., et al.

v.

Helsinn Healthcare S.A., et al.

U.S. Patent No. 8,729,094

© 2015 Evaluate Ltd. ALL RIGHTS RESERVED.

Inserted from <<http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=35999>>